$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq

$seelq Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000101749116000234 Filed on November 08, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$0.00	$4.317M	$1.273M
YoY Change	-100.0%	239.12%	-32.93%
Cost Of Revenue		$111.0K	$142.0K
YoY Change		-21.83%
Gross Profit		$826.0K	$1.131M
YoY Change		-26.97%	-19.96%
Gross Profit Margin		19.13%	88.85%
Selling, General & Admin	$1.900M	$1.550M	$2.410M
YoY Change	-18.8%	-35.68%	-11.4%
% of Gross Profit		187.65%	213.09%
Research & Development	$610.0K	$170.0K	$4.611M
YoY Change	-83.33%	-96.31%	145.79%
% of Gross Profit		20.58%	407.69%
Depreciation & Amortization	-$110.0K	$70.00K	$70.00K
YoY Change	-237.5%	0.0%	16.67%
% of Gross Profit		8.47%	6.19%
Operating Expenses	$2.510M	$1.720M	$7.023M
YoY Change	-58.17%	-75.51%	52.84%
Operating Profit		-$1.720M	-$5.892M
YoY Change		-70.81%	85.17%
Interest Expense	$2.200M	-$234.0K	-$267.0K
YoY Change	-25.42%	-12.36%	506.82%
% of Operating Profit
Other Income/Expense, Net	$0.00	$124.0K	$858.0K
YoY Change	-100.0%	-85.55%	1616.0%
Pretax Income	-$320.0K	-$1.600M	-$5.030M
YoY Change	-86.27%	-68.19%	60.7%
Income Tax		$1.000K	$0.00
% Of Pretax Income
Net Earnings	-$300.0K	-$1.291M	-$5.034M
YoY Change	-87.14%	-74.35%	61.71%
Net Earnings / Revenue		-29.91%	-395.44%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.154M	-$5.864M	-$29.59M
COMMON SHARES
Basic Shares Outstanding	7.733M shares	66.35M shares	50.41M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.090M	$5.610M	$5.810M
YoY Change	-46.27%	-3.44%	-63.94%
Cash & Equivalents	$2.087M	$5.614M	$5.809M
Short-Term Investments
Other Short-Term Assets	$1.550M	$420.0K	$1.640M
YoY Change	15.67%	-74.39%	47.75%
Inventory	$764.0K	$800.0K	$142.0K
Prepaid Expenses
Receivables	$530.0K	$398.0K	$575.0K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$3.634M	$7.236M	$8.165M
YoY Change	-41.55%	-11.38%	-55.55%
LONG-TERM ASSETS
Property, Plant & Equipment	$164.0K	$1.091M	$1.294M
YoY Change	-87.29%	-15.69%	-1.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$60.00K	$83.00K	$141.0K
YoY Change	-78.1%	-41.13%	33.02%
Total Long-Term Assets	$1.066M	$1.174M	$1.435M
YoY Change	-31.84%	-18.19%	0.7%
TOTAL ASSETS
Total Short-Term Assets	$3.634M	$7.236M	$8.165M
Total Long-Term Assets	$1.066M	$1.174M	$1.435M
Total Assets	$4.700M	$8.410M	$9.600M
YoY Change	-39.6%	-12.4%	-51.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$760.0K	$1.430M	$420.0K
YoY Change	-51.9%	240.48%	-65.57%
Accrued Expenses	$1.333M	$3.144M	$2.869M
YoY Change	-60.13%	9.59%	57.21%
Deferred Revenue
YoY Change
Short-Term Debt	$6.650M	$7.370M	$2.680M
YoY Change	-29.26%	175.0%	123.33%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.29M	$12.61M	$6.855M
YoY Change	-27.99%	83.89%	7.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$7.190M
YoY Change		-100.0%
Other Long-Term Liabilities	$76.00K	$80.00K	$190.0K
YoY Change	-62.0%	-57.89%	227.59%
Total Long-Term Liabilities	$76.00K	$80.00K	$190.0K
YoY Change	-62.0%	-57.89%	227.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.29M	$12.61M	$6.855M
Total Long-Term Liabilities	$76.00K	$80.00K	$190.0K
Total Liabilities	$12.22M	$15.95M	$17.51M
YoY Change	-31.08%	-8.93%	124.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$316.3M	-$316.0M	-$306.5M
YoY Change	2.41%	3.09%	12.47%
Common Stock	$308.8M	$308.5M	$298.6M
YoY Change	3.3%	3.3%	4.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$7.516M	-$7.537M	-$7.911M
YoY Change
Total Liabilities & Shareholders Equity	$4.700M	$8.410M	$9.600M
YoY Change	-39.6%	-12.4%	-51.51%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	-$300.0K	-$1.291M	-$5.034M
YoY Change	-87.14%	-74.35%	61.71%
Depreciation, Depletion And Amortization	-$110.0K	$70.00K	$70.00K
YoY Change	-237.5%	0.0%	16.67%
Cash From Operating Activities	-$2.710M	-$860.0K	-$6.590M
YoY Change	106.87%	-86.95%	61.52%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$30.00K
YoY Change	-100.0%	-100.0%	-57.14%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$10.00K
YoY Change		-100.0%
Cash From Investing Activities	$10.00K	$0.00	-$20.00K
YoY Change	-108.33%	-100.0%	-66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-830.0K	3.750M	4.990M
YoY Change	69.39%	-24.85%	75.7%
NET CHANGE
Cash From Operating Activities	-2.710M	-860.0K	-6.590M
Cash From Investing Activities	10.00K	0.000	-20.00K
Cash From Financing Activities	-830.0K	3.750M	4.990M
Net Change In Cash	-3.530M	2.890M	-1.620M
YoY Change	83.85%	-278.4%	24.62%
FREE CASH FLOW
Cash From Operating Activities	-$2.710M	-$860.0K	-$6.590M
Capital Expenditures	$0.00	$0.00	-$30.00K
Free Cash Flow	-$2.710M	-$860.0K	-$6.560M
YoY Change	127.73%	-86.89%	63.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	apri	Class Of Warrant Or Right Expiration Period ClassOfWarrantOrRightExpirationPeriod	P5Y6M
CY2016Q3	apri	Entity Public Float Primary Public Offerings Of Securities Threshold EntityPublicFloatPrimaryPublicOfferingsOfSecuritiesThreshold	75000000	USD
	apri	Issuance Of Common Stock And Warrants Value IssuanceOfCommonStockAndWarrantsValue	7865000	USD
CY2016Q3	apri	License Fees Expected Future Proceeds LicenseFeesExpectedFutureProceeds	136656000	USD
CY2016Q3	apri	License Fees Expected Future Proceedson Commercial Launch Payments LicenseFeesExpectedFutureProceedsonCommercialLaunchPayments	27622000	USD
CY2016Q3	apri	License Fees Expected Future Proceedson Regulatory Milestones LicenseFeesExpectedFutureProceedsonRegulatoryMilestones	4475000	USD
CY2016Q3	apri	License Fees Expected Future Proceedson Sales Milestones LicenseFeesExpectedFutureProceedsonSalesMilestones	104559000	USD
CY2016Q3	apri	Public Float Primary Public Offerings Of Securities Percent Of Public Float Eligible To Be Raised If Under Threshold PublicFloatPrimaryPublicOfferingsOfSecuritiesPercentOfPublicFloatEligibleToBeRaisedIfUnderThreshold	0.3333
CY2015Q4	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	2228000	USD
CY2016Q3	apri	Research And Development Accrued Expense ResearchAndDevelopmentAccruedExpense	627000	USD
CY2016Q3	apri	Sales Revenue Goods Net Third Party Components SalesRevenueGoodsNetThirdPartyComponents	200000	USD
	apri	Sales Revenue Goods Net Third Party Components SalesRevenueGoodsNetThirdPartyComponents	400000	USD
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1154
	apri	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.1133
CY2016Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	74100000	USD
CY2014Q3	apri	Shelf Registration Statement Available Amount ShelfRegistrationStatementAvailableAmount	100000000	USD
CY2016Q3	apri	Stock Sale Restriction Period StockSaleRestrictionPeriod	P90D
CY2016Q3	apri	Working Capital WorkingCapital	-5400000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001017491
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7733205	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	APRICUS BIOSCIENCES, INC.
	dei	Trading Symbol TradingSymbol	APRI
CY2015Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1580000	USD
CY2016Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1434000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	519000	USD
CY2016Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	398000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	209000	USD
	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	282000	USD
CY2015Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1223000	USD
CY2016Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	656000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3343000	USD
CY2016Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3144000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	466000	USD
CY2016Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	957000	USD
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	298926000	USD
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	308464000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1427000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	299000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	912000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	333000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1427000	USD
CY2015Q4	us-gaap	Assets Assets	7781000	USD
CY2016Q3	us-gaap	Assets Assets	8410000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	6217000	USD
CY2016Q3	us-gaap	Assets Current AssetsCurrent	7236000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	259000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11400000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5809000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3887000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5614000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5591000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1727000	USD
CY2016Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.75	shares
CY2016Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2317847	shares
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5041526	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7733205	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5041526	shares
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7733205	shares
CY2016Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	10000000	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	5000	USD
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	142000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	884000	USD
CY2016Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	111000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	437000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-391000	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	10000	USD
	us-gaap	Decrease In Restricted Cash DecreaseInRestrictedCash	280000	USD
CY2015Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	135000	USD
CY2016Q3	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	0	USD
CY2015Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	178000	USD
CY2016Q3	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	179000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	65000	USD
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	80000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	137000	USD
CY2016Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	224000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	217000	USD
CY2015Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1841000	USD
CY2016Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3300000	USD
CY2016Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3261000	USD
CY2015Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	5100000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.00
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.37
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.17
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1193000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1804000	USD
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-626000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5063000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-56000	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2412000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8177000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1815000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6513000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	1131000	USD
	us-gaap	Gross Profit GrossProfit	1326000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	826000	USD
	us-gaap	Gross Profit GrossProfit	1590000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-5034000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-16691000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1290000	USD
	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-7127000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-443000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-225000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-103000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-121000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1686000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-233000	USD
	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-318000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1219000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-137000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-133000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	140000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	12000	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-18000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-163000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-119000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	718000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-638000	USD
CY2015Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	300000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	600000	USD
CY2016Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	200000	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	800000	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-267000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-594000	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-251000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-788000	USD
	us-gaap	Interest Paid InterestPaid	340000	USD
	us-gaap	Interest Paid InterestPaid	508000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	469000	USD
CY2016Q3	us-gaap	Inventory Net InventoryNet	800000	USD
CY2015Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	145000	USD
CY2016Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	350000	USD
CY2015Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	324000	USD
CY2016Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	450000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	17725000	USD
CY2016Q3	us-gaap	Liabilities Liabilities	15947000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7781000	USD
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8410000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15684000	USD
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	12606000	USD
CY2015Q3	us-gaap	License Costs LicenseCosts	0	USD
	us-gaap	License Costs LicenseCosts	0	USD
CY2016Q3	us-gaap	License Costs LicenseCosts	3380000	USD
	us-gaap	License Costs LicenseCosts	3380000	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	1000000	USD
	us-gaap	Licenses Revenue LicensesRevenue	1350000	USD
CY2016Q3	us-gaap	Licenses Revenue LicensesRevenue	3950000	USD
	us-gaap	Licenses Revenue LicensesRevenue	4000000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15947000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11828000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-206000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	262000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21332000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10363000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-5034000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16691000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1291000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-7134000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	858000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1146000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	108000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3798000	USD
CY2015Q4	us-gaap	Notes Payable Current NotesPayableCurrent	9401000	USD
CY2016Q3	us-gaap	Notes Payable Current NotesPayableCurrent	7372000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	7023000	USD
	us-gaap	Operating Expenses OperatingExpenses	19163000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	2224000	USD
	us-gaap	Operating Expenses OperatingExpenses	12515000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-5892000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17837000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1398000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10925000	USD
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	471000	USD
CY2016Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	234000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	274000	USD
CY2016Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	83000	USD
CY2015Q4	us-gaap	Other Employee Related Liabilities Current And Noncurrent OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent	0	USD
CY2016Q3	us-gaap	Other Employee Related Liabilities Current And Noncurrent OtherEmployeeRelatedLiabilitiesCurrentAndNoncurrent	1147000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	200000	USD
CY2016Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	80000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-68000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-64000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000	USD
CY2016Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	400000	USD
CY2015Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	100000	USD
CY2016Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3200000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	216000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1062000	USD
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	424000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10869000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14144000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10900000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2200000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7800000	USD
CY2016Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3700000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10986000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	409000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6002000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	280000	USD
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-308875000	USD
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-316009000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	9600000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	83000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1290000	USD
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1091000	USD
CY2015Q3	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	0	USD
CY2016Q3	us-gaap	Recapitalization Costs RecapitalizationCosts	256000	USD
	us-gaap	Recapitalization Costs RecapitalizationCosts	461000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	5000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2311000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4611000	USD
CY2015Q3	us-gaap	Royalty Revenue RoyaltyRevenue	188000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	351000	USD
CY2016Q3	us-gaap	Royalty Revenue RoyaltyRevenue	195000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	866000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	85000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	509000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	172000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	541000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1273000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	2210000	USD
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	4317000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5407000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	912000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1427000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0187
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0178
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0137
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0136
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	82000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	167000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.23
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	405000	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	490000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.46
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.82
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.16
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.57
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	249000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	249000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-9944000	USD
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	-7537000	USD
CY2016Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	1700000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5042000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4950000	shares
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6632000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	6108000	shares

Files In Submission

Name	View Source	Status
0001017491-16-000234-index-headers.html	Edgar Link	pending
0001017491-16-000234-index.html	Edgar Link	pending
0001017491-16-000234.txt	Edgar Link	pending
0001017491-16-000234-xbrl.zip	Edgar Link	pending
apri-20160930.xml	Edgar Link	completed
apri-20160930.xsd	Edgar Link	pending
apri-20160930_cal.xml	Edgar Link	unprocessable
apri-20160930_def.xml	Edgar Link	unprocessable
apri-20160930_lab.xml	Edgar Link	unprocessable
apri-20160930_pre.xml	Edgar Link	unprocessable
apri9301610q.htm	Edgar Link	pending
apri93016ex311.htm	Edgar Link	pending
apri93016ex312.htm	Edgar Link	pending
apri93016ex321.htm	Edgar Link	pending
apri93016ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq

2016 Q4 Form 10-Q Financial Statement

#000101749116000234 Filed on November 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEELQ SEELOS THERAPEUTICS, INC. Stock $seelq

2016 Q4 Form 10-Q Financial Statement

#000101749116000234 Filed on November 08, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SEELQ
SEELOS THERAPEUTICS, INC. Stock $seelq